116 related articles for article (PubMed ID: 26518748)
1. Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma.
Dunleavy K; Pittaluga S; Shovlin M; Roschewski M; Lai C; Steinberg SM; Jaffe ES; Wilson WH
Haematologica; 2016 Jan; 101(1):e27-9. PubMed ID: 26518748
[No Abstract] [Full Text] [Related]
2. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
Maeda Y; Nishimori H; Yoshida I; Hiramatsu Y; Uno M; Masaki Y; Sunami K; Masunari T; Nawa Y; Yamane H; Gomyo H; Takahashi T; Yano T; Matsuo K; Ohshima K; Nakamura S; Yoshino T; Tanimoto M
Haematologica; 2017 Dec; 102(12):2097-2103. PubMed ID: 28971899
[TBL] [Abstract][Full Text] [Related]
3. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients.
Sibon D; Nguyen DP; Schmitz N; Suzuki R; Feldman AL; Gressin R; Lamant L; Weisenburger DD; Rosenwald A; Nakamura S; Ziepert M; Maurer MJ; Bast M; Armitage JO; Vose JM; Tilly H; Jais JP; Savage KJ
Haematologica; 2019 Dec; 104(12):e562-e565. PubMed ID: 31004022
[No Abstract] [Full Text] [Related]
4. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.
Cederleuf H; Bjerregård Pedersen M; Jerkeman M; Relander T; d'Amore F; Ellin F
Br J Haematol; 2017 Sep; 178(5):739-746. PubMed ID: 28485010
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous involvement in systemic anaplastic large cell lymphoma.
Kwok C; Salmo E
J Dtsch Dermatol Ges; 2015 Jul; 13(7):693-5. PubMed ID: 26031654
[No Abstract] [Full Text] [Related]
7. Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma.
Foyil KV; Kennedy DA; Grove LE; Bartlett NL; Cashen AF
Leuk Lymphoma; 2012 Mar; 53(3):506-7. PubMed ID: 21867368
[No Abstract] [Full Text] [Related]
8. Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma.
Major A; Pan Z; Kamdar M
Am J Hematol; 2017 Nov; 92(11):1267-1268. PubMed ID: 28370436
[No Abstract] [Full Text] [Related]
9. [Clinical features and prognosis for anaplastic large cell lymphoma].
Dong F; Liu Y; Li Q; Wang J; Jing H; Ke X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Jun; 43(6):631-637. PubMed ID: 30110005
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.
Isogai R; Fukao M; Kawada A
J Dermatol; 2007 Aug; 34(8):556-60. PubMed ID: 17683387
[TBL] [Abstract][Full Text] [Related]
11. Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative.
Kawamoto K; Suzuki T; Kasami T; Kiryu M; Sone H; Miyoshi H; Ohshima K; Takizawa J
Hematol Oncol; 2019 Apr; 37(2):212-214. PubMed ID: 30394560
[No Abstract] [Full Text] [Related]
12. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
13. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
14. "Double hit" anaplastic large cell lymphoma with concurrent ALK and MYC rearrangements.
Luo DX; Li W; Ye MT; Yang Y; Tang G; You MJ
Am J Hematol; 2020 Dec; 95(12):1625-1627. PubMed ID: 32833271
[No Abstract] [Full Text] [Related]
15. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759
[TBL] [Abstract][Full Text] [Related]
16. Treatment of AIDS-associated anaplastic large-cell lymphoma with dose-adjusted EPOCH chemotherapy.
Nagajothi N; Dham SK; Gelfand Y; Sanmugarajah J
J Natl Med Assoc; 2007 Jul; 99(7):799-801. PubMed ID: 17668647
[TBL] [Abstract][Full Text] [Related]
17. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
[TBL] [Abstract][Full Text] [Related]
18. Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma.
Fedele PL; Gregory GP; Gilbertson M; Shortt J; Kumar B; Opat S; Grigoriadis G
Ann Hematol; 2016 Mar; 95(4):667-8. PubMed ID: 26801792
[No Abstract] [Full Text] [Related]
19. Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma.
García-Suárez J; Flores E; Callejas M; Arribas I; Gil-Fernández JJ; Olmedilla G; Curto N; Guillén H; Casco CR; Martín Y; Burgaleta C
Br J Haematol; 2013 Feb; 160(4):510-4. PubMed ID: 23228045
[TBL] [Abstract][Full Text] [Related]
20. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
